Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
Review on Mesothelin in Mesothelioma, in Journal of Clinical Oncology (2016), one of the most cited Europe PMC records with Mesothelin in its title.
Overview
Mesothelin is a tumor antigen that is highly expressed in many human cancers, including malignant mesothelioma and pancreatic, ovarian, and lung adenocarcinomas. It is an attractive target for cancer immunotherapy because its normal expression is limited to mesothelial cells, which are dispensable. Several antibody-based therapeutic agents as well as vaccine and T-cell therapies directed at mesothelin are undergoing clinical evaluation. These include antimesothelin immunotoxins (SS1P, RG7787/LMB-100), chimeric antimesothelin antibody (amatuximab), mesothelin-directed antibody drug conjugates (anetumab ravtansine, DMOT4039A, BMS-986148), live attenuated Listeria monocytogenes-expressing mesothelin (CRS-207, JNJ-64041757), and chimeric antigen receptor T-cell therapies. Two antimesothelin agents are currently in multicenter clinical registration trials for malignant mesothelioma: amatuximab in the first-line setting and anetumab ravtansine as second-line therapy. Phase II randomized clinical trials of CRS-207 as a boosting agent and in combination with immune checkpoint inhibition for pancreatic cancer are nearing completion. These ongoing studies will define the utility of mesothelin immunotherapy for treating cancer.
Indexed on Europe PMC as PubMed record 27863199 (DOI 10.1200/jco.2016.68.3672). Its title names Mesothelin and its text names Mesothelioma; PubMed types it as a review (research-article, Review). It was matched automatically to the idea "Treat the body cavity, not the bloodstream, for surface spread" and no figure has been checked by an editor.
One of the most cited reviews Europe PMC returns for Mesothelin in Mesothelioma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
- Matched by Mesothelin in the title and Mesothelioma in the title or abstract of the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.
- A review summarises other studies; the primary reports it cites are the evidence.
Similar pages
not linked directly; found by shared links- Key paperMesothelin: a new target for immunotherapy
Shares Regionally delivered mesothelin CAR-T with PD-1 blockade, Antibody-drug conjugates for mesothelioma: why they have failed so far and how they could work, Treat the body cavity, not the bloodstream, for surface spread.
- Key paperMesothelin-Targeted CARs: Driving T Cells to Solid Tumors
Shares Regionally delivered mesothelin CAR-T with PD-1 blockade, Antibody-drug conjugates for mesothelioma: why they have failed so far and how they could work, Treat the body cavity, not the bloodstream, for surface spread.
- TargetMesothelin
Shares Regionally delivered mesothelin CAR-T with PD-1 blockade, Antibody-drug conjugates for mesothelioma: why they have failed so far and how they could work, Treat the body cavity, not the bloodstream, for surface spread.